CLARIFY registry to improve understanding and management of heart disease
MONTREAL, Aug. 31 /CNW Telbec/ - CLARIFY, the largest international
registry to ever be carried out in stable coronary artery disease (CAD)
patients was launched today in 40 countries, including Canada, at the European
Society of Cardiology (ESC) Congress.
The CLARIFY registry (ProspeCtive observational LongitudinAl RegIstry oF
patients with stable coronary arterY disease) is designed to increase
knowledge and understanding of CAD and will provide important epidemiological
and clinical data, including an assessment of the role of heart rate in the
prognosis of CAD patients.
Coronary artery disease remains the leading cause of death worldwide.
Improved understanding of the management and outcomes of these patients is
paramount to reducing the disease burden. Data available today on the
presentation and management of CAD stem mainly from randomised clinical trials
or registries which have limited generalisability due to the stringent
selection process of participants or the focus on a particular manifestation
of the disease. There are only limited contemporary data regarding stable
outpatients with CAD, their management and outcomes.
CLARIFY is a prospective, observational, longitudinal registry of stable
coronary artery disease (CAD) outpatients. The registry will be representative
of CAD patients seen by cardiologists and primary care physicians in daily
clinical practice. A minimum of 30,000 outpatients with stable CAD from around
40 countries worldwide will be followed up for five years. Data will be
collected prospectively at annual visits (12, 24, 36, 48 and 60 months).
The overall aim of CLARIFY is to characterise contemporary CAD patients
in terms of their demographic characteristics, clinical profiles, management
and outcomes. CLARIFY will also determine long-term prognostic factors in this
group of patients with a view to developing a powerful and comprehensive risk
prediction model, including all potential prognostic factors, including
resting heart rate.
The CLARIFY registry is funded by an educational grant from Servier
Research Group an independent pharmaceutical company. Data will be collected
and analysed at the Robertson Centre for Biostatistics, Glasgow, UK, under the
guidance of Prof Ian Ford, and the study is led by an executive steering
committee composed of international experts in the field of CAD.
About Coronary Artery Disease
Coronary artery disease (CAD) is the most common manifestation of
cardiovascular disease. It refers to the hardening and shrinking of the
coronary arteries (atherosclerosis) which leads to diminished blood flow and
reduces oxygen supply to the heart muscle (ischemia). The lack of oxygen
supply to the heart muscle may cause angina (chest pain). If the coronary
artery becomes completely blocked, a whole section of the heart muscle is
deprived of oxygen and dies, resulting in a myocardial infarction (MI) or
heart attack. Coronary artery disease is a progressive, often silent disease
that is most often unobserved until the first symptoms of ischemia or MI
occur. Although the prognosis of patients with CAD has been greatly improved
by advances in cardiovascular treatment, it is still the most frequent cause
Cardiovascular disease accounts for the death of more Canadians than any
other disease. In fact, in Canada someone dies every seven minutes from it.
According to the latest statistics available from Statistics Canada, in 2005
cardiovascular disease accounted for close to one third of all deaths in
Canada (more than 71,000 deaths).(1)
About Servier Canada Inc.
Servier Canada Inc. (www.servier.ca) is a pharmaceutical company, based
in Laval (Quebec) that focuses on the development of therapies to treat
cardiovascular, metabolic and central nervous system diseases. It is the
Canadian subsidiary of the Servier Research Group, the leading French-based
independent (private) pharmaceutical company, which is present in 140
countries around the world.
The Servier Research Group distinguishes itself by investing 25 per cent
of its income in research and development which is approximately double the
industry average. This enables the advancement of scientific knowledge and the
discovery of therapeutic innovations leading to improved patient care and
(1) Heart and Stroke Foundation of Canada. Statistics: Cardiovascular
disease deaths. Available at:
Last accessed: August 26, 2009.
For further information:
For further information: Geneviève Déry, HKDP Communications and public
affairs, (514) 395-0375, ext. 232, (514) 219-2764, firstname.lastname@example.org